

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
Under the Securities Exchange Act of 1934

For the Month of December 2025

001-36203  
(Commission File Number)

**CAN-FITE BIOPHARMA LTD.**  
(Exact name of Registrant as specified in its charter)

**26 Ben Gurion Street  
Ramat Gan 5257346 Israel**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

---

---

The press release attached hereto as Exhibit 99.1 is hereby incorporated by reference into the registrant's Registration Statements on Form S-8 (File Nos. [333-227753](#), [333-271384](#) and [333-278525](#)) and Form F-3 (File Nos. [333-236064](#), [333-274316](#), [333-262055](#), [333-276000](#) and [333-281872](#)), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On December 26, 2025, Can-Fite BioPharma Ltd. issued a press release entitled "Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction." A copy of this press release is furnished herewith as Exhibit 99.1.

## EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description</b>
--------------------	--------------------

99.1	<a href="#">Press Release dated December 26, 2025</a>
------	---

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: December 29, 2025

By: /s/ Motti Farbstein  
Motti Farbstein  
Chief Executive Officer and  
Chief Financial Officer

**Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction**

RAMAT GAN, Israel, December 26, 2025 — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced that the Brazilian Patent Office (INPI) has granted Patent No. BR112015002697-4, entitled “Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction.”

The granted patent provides intellectual-property protection in Brazil for the use of Can-Fite’s proprietary A3AR agonists in the treatment of sexual dysfunction, further strengthening the Company’s global patent portfolio. Brazil represents one of the largest pharmaceutical markets in Latin America, with a growing demand for innovative therapies addressing sexual health conditions.

Sexual dysfunction is associated with vascular, inflammatory, and metabolic pathways. Preclinical and clinical data generated by Can-Fite suggest that activation of the A3 adenosine receptor may modulate key signaling mechanisms involved in erectile and sexual function, supporting the therapeutic rationale underlying the patent.

“The grant of this Brazilian patent further validates the therapeutic versatility of A3 adenosine receptor agonists and expands our intellectual-property footprint in a major pharmaceutical market,” said Pnina Fishman, Ph.D., Chairperson and Chief Scientific Officer of Can-Fite BioPharma. “This patent complements our broader clinical and preclinical programs and may create future partnering or commercialization opportunities in Latin America.”

Can-Fite continues to advance its A3AR agonist platform across multiple indications, including oncology, inflammatory diseases, and additional non-oncologic conditions, while actively evaluating strategic opportunities to maximize the value of its patent estate.

**About Can-Fite BioPharma Ltd.**

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: <https://www.canfite.com/>.

---

## **Forward-Looking Statements**

This press release contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its expectations regarding potential opportunities in Latin America. All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 7, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

## **Contact**

Can-Fite BioPharma  
Motti Farbstein  
[info@canfite.com](mailto:info@canfite.com)  
+972-3-9241114

---